Zacks Research Issues Optimistic Estimate for THC Earnings

Tenet Healthcare Corporation (NYSE:THC) – Analysts at Zacks Research raised their Q3 2026 EPS estimates for Tenet Healthcare in a research note issued on Thursday, August 13th. Zacks Research analyst Team now expects that the company will post earnings per share of $4.34 for the quarter, up from their prior estimate of $4.13. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Tenet Healthcare’s current full-year earnings is $21.07 per share. Zacks Research also issued estimates for Tenet Healthcare’s Q1 2027 earnings at $4.63 EPS and Q1 2028 earnings at $4.52 EPS.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share for the quarter, beating the consensus estimate of $4.26 by $1.86. The firm had revenue of $6.04 billion for the quarter, compared to analyst estimates of $5.43 billion. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.02 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS.

Several other research firms also recently commented on THC. Truist Financial boosted their price objective on Tenet Healthcare from $270.00 to $290.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. KeyCorp reduced their price target on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Guggenheim upped their price objective on shares of Tenet Healthcare from $242.00 to $283.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Royal Bank Of Canada lifted their price objective on shares of Tenet Healthcare from $236.00 to $283.00 and gave the company an “outperform” rating in a report on Monday, July 27th. Finally, Wells Fargo & Company upped their target price on shares of Tenet Healthcare from $231.00 to $281.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $272.25.

Tenet Healthcare Stock Up 0.2%

THC stock opened at $267.40 on Friday. The stock’s 50 day simple moving average is $208.09 and its 200 day simple moving average is $203.48. The company has a market cap of $21.53 billion, a P/E ratio of 10.31, a price-to-earnings-growth ratio of 1.02 and a beta of 1.23. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.35 and a current ratio of 1.41. Tenet Healthcare has a fifty-two week low of $157.58 and a fifty-two week high of $270.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in THC. Triumph Capital Management bought a new position in shares of Tenet Healthcare during the 3rd quarter valued at approximately $25,000. Activest Wealth Management purchased a new position in Tenet Healthcare in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC bought a new position in Tenet Healthcare during the fourth quarter valued at $29,000. Canada Pension Plan Investment Board purchased a new stake in Tenet Healthcare in the second quarter worth $35,000. Finally, Trust Co. of Vermont bought a new stake in shares of Tenet Healthcare in the second quarter valued at $37,000. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director J Robert Kerrey sold 5,638 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total transaction of $983,943.76. Following the completion of the sale, the director directly owned 16,804 shares of the company’s stock, valued at $2,932,634.08. This trade represents a 25.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Lisa Y. Foo sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $258.03, for a total transaction of $2,580,300.00. Following the completion of the transaction, the executive vice president directly owned 32,053 shares in the company, valued at $8,270,635.59. This trade represents a 23.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 41,375 shares of company stock valued at $9,793,347 over the last quarter. Corporate insiders own 0.97% of the company’s stock.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.